Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Assets (2016 - 2025)

Amphastar Pharmaceuticals has reported Assets over the past 13 years, most recently at $1.6 billion for Q4 2025.

  • Quarterly results put Assets at $1.6 billion for Q4 2025, up 3.29% from a year ago — trailing twelve months through Dec 2025 was $1.6 billion (up 3.29% YoY), and the annual figure for FY2025 was $1.6 billion, up 3.29%.
  • Assets for Q4 2025 was $1.6 billion at Amphastar Pharmaceuticals, down from $1.7 billion in the prior quarter.
  • Over the last five years, Assets for AMPH hit a ceiling of $1.7 billion in Q3 2025 and a floor of $645.7 million in Q1 2021.
  • Median Assets over the past 5 years was $1.4 billion (2023), compared with a mean of $1.2 billion.
  • Biggest five-year swings in Assets: surged 112.56% in 2023 and later rose 0.04% in 2024.
  • Amphastar Pharmaceuticals' Assets stood at $671.5 million in 2021, then increased by 10.49% to $742.0 million in 2022, then surged by 103.9% to $1.5 billion in 2023, then rose by 4.27% to $1.6 billion in 2024, then rose by 3.29% to $1.6 billion in 2025.
  • The last three reported values for Assets were $1.6 billion (Q4 2025), $1.7 billion (Q3 2025), and $1.6 billion (Q2 2025) per Business Quant data.